Delivery Order SPE2DB22D1106-SPE2DB25FEQV0
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,389.54 to AmerisourceBergen Drug Corp for the supply of Neulasta Onpro 6 mg/0.6 ml injectable kits, with an ultimate completion date of December 4, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award to the vendor's Conshohocken, Pennsylvania location. This delivery order is issued under AmerisourceBergen's prime Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $1,237.65 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Neulasta OnPro 6 mg/0.6 mL Kit on December 9, 2025, with a completion date of December 10, 2025. This non-set-aside competitive award is a child contract executed under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The delivery will be performed at...
- This is a $2,465.76 firm-fixed price delivery order awarded to Amerisourcebergen Drug Corp's Corporate Office Division by the Defense Logistics Agency (DLA) Troop Support Medical for the supply of Neulasta OnPro 6 mg/0.6 ml kits. The order is part of Amerisourcebergen's larger $999,999,999.00 Indefinite Delivery Contract with DLA to provide a comprehensive range of pharmaceutical products and medical supplies to support the Department of Defense's global military treatment programs and...
- The Defense Logistics Agency awarded a $28,076.54 delivery order to AmerisourceBergen Drug Corp for Neulasta 6 mg/0.6 ml syringes on August 12, 2025, with an ultimate completion date of August 13, 2025. This firm fixed price contract represents a non-competitive set-aside delivery order utilizing the company's existing Indefinite Delivery Contract with DLA Troop Support Medical. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $27,729.49, is for the supply of Neulasta OnPro 6 mg/0.6 ml kits to support federal healthcare programs, particularly military and veterans' healthcare systems. The contract has an ultimate completion date of February 4, 2025. AmerisourceBergen holds a significant Indefinite...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $17,831.39, is for the delivery of NEULASTA ONPRO 6 MG/0.6 ML KIT 0.6ML, a specialty medication. This contract does not have a set-aside designation, indicating it was competed openly. AmerisourceBergen is the prime contractor, and the contract has an ultimate completion date of...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Neulasta OnPro 6 mg/0.6 ml kits, a medication used to reduce the risk of infection in cancer patients undergoing chemotherapy. The contract has a ceiling value of $13,074.00 and a completion date of July 10, 2025. It is a firm fixed-price contract, which indicates the price is...
- This contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $28,695.17 firm-fixed-price delivery order is for NEULASTA ONPRO 6 MG/0.6 ML KIT 0.6ML, a specialty medication, to support military healthcare programs. The award is not designated as a set-aside contract. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Neulasta, a specialty medication, with a ceiling value of $95,008.32. This is a firm fixed price delivery order contract and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a $1,934.37 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Neupogen (filgrastim) 480 mcg/1.6 mL vials. The contract, awarded on August 21, 2025, with an ultimate completion date of August 22, 2025, represents a single delivery of this granulocyte-colony stimulating factor medication used to support patients undergoing chemotherapy and other medical treatments. This delivery order was competitively awarded with no set-aside...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FEQV0Delivery Order
The Defense Logistics Agency awarded a $11,686.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Neulasta OnPro 6 mg/0.6 mL kits, with an ultimate completion date of June 2, 2025. This non-set-aside contract represents a single delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal military and veteran healthcare systems, leveraging its comprehensive supply chain capabilities to fulfill medical procurement needs. This delivery order falls within AmerisourceBergen's broader role as a pharmaceutical prime vendor for the Defense Health Agency and other federal healthcare systems. Neulasta OnPro is a supportive care medication commonly used in oncology settings to help prevent infection in cancer patients undergoing chemotherapy. The award demonstrates the company's continued capacity to deliver specialized pharmaceutical products through competitive procurement processes, maintaining its significant position as a primary supplier of branded and generic medications, vaccines, and medical supplies across the military healthcare enterprise.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.7k | 5/30/25 |